Artificial intelligence has moved from pilot projects to a central role in many life sciences strategies. What began as a set ...
Hosted on MSN
AlphaFold opens new doors in drug development—how
AlphaFold, a transformative AI-driven tool developed by DeepMind, has revolutionized the field of structural biology by accurately predicting protein structures. This breakthrough holds significant ...
Overview Artificial intelligence seems to be transforming drug discovery in 2026, enabling faster molecule design, smarter clinical trials, and reduced R&D ...
VivaMed BioPharma (VivaMed), a clinical-stage pharmaceutical company leveraging Artificial Intelligence (AI) to discover and advance repurposed and improved therapeutic assets, today announced a ...
Explore the role of BD&L in R&D decision-making. Understand its impact on funding and market intelligence for scientists.
The Mystra platform, developed over 10 years, offers biopharma partners proven analytical power to turn months of R&D into minutes, dramatically increasing the availability of quality genetic insights ...
The Mark Foundation for Cancer Research today announced four recipients of the 2026 Drug Discovery Awards, a program designed to bridge the gap between academic discovery and clinical application.
Aptamer Group plc, the developer of next-generation synthetic binders for the life sciences industry, today announced a new contract valued at up to £617,000 with a top-five pharmaceutical company.
Neuroinflammation drives the progression of neurodegenerative disorders like Alzheimer's, Parkinson's, and multiple sclerosis ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results